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Abstract: Non-alcoholic fatty liver disease is marked by hepatic fat accumulation not due 
to alcohol abuse. Several studies have demonstrated that NAFLD is associated with insulin 
resistance leading to a resistance in the antilipolytic effect of insulin in the adipose tissue 
with an increase of free fatty acids (FFAs). The increase of FFAs induces mitochondrial 
dysfunction and development of lipotoxicity. Moreover, in subjects with NAFLD, ectopic 
fat also accumulates as cardiac and pancreatic fat. In this review we analyzed the 
mechanisms that relate NAFLD with metabolic syndrome and dyslipidemia and its 
association with the development and progression of cardiovascular disease. 
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1. Introduction 
Non-alcoholic fatty liver disease (NAFLD) has been considered a benign disease often associated 
with central obesity and insulin resistance and in general with factors of the metabolic syndrome 
(Figure 1). However, recent studies have highlighted that NAFLD is a chronic condition, ranging  
from benign steatosis, (i.e., hepatic triglyceride accumulation >5.5% using magnetic resonance  
imaging [1,2] or >5% corresponding to 50 mg/g by wet weight), to more significant liver injury 
including lobular inflammation, hepatocyte ballooning, fibrosis and cirrhosis, i.e., non-alcoholic 
steato-hepatitis (NASH) [3]. 
Excess liver fat is extremely common and prevalence of NAFLD has been increasing mainly 
because of the increased prevalence of obesity. It has been estimated that as many as 30% of adults in 
USA and other Western countries have NAFLD [4]. The real prevalence is unknown since NAFLD is 
often undiagnosed and most subjects with NAFLD, even those with diabetes, have normal liver 
aminotransferases and clinicians do not suspect the potential presence of NAFLD [5–7]. NAFLD is 
more prevalent among obese subjects and also in patients with type 2 diabetes independently of degree 
of obesity [7]. The prevalence increases to 57% in obese subjects, 70% in diabetic subjects and 90% in 
morbidly obese people. On the other hand NASH may be present in up to 3% of the general population 
and in up to two thirds of individuals with morbid obesity and/or type 2 diabetes [4,8]. In addition to 
hepatic complications, patients with NAFLD are at increased risk for cardio-metabolic complications 
such as type 2 diabetes (T2DM) and cardiovascular disease (CVD) [4,9]. 
In this article we have reviewed the current literature trying to highlight the mechanisms that are 
responsible for the development of NAFLD and that are at the base for the increased cardiometabolic 
risk in patients with NAFLD. 
2. Insulin Resistance and the Development of NAFLD 
Several studies have highlighted that insulin resistance is a characteristic feature of NAFLD [10–12], 
even when subjects are not obese [13]. However, NAFLD per se cannot be considered a cause  
for insulin resistance but rather a consequence as shown by studies in subjects genetically  
predisposed to NAFLD. In fact subjects with either mutation for PNPLA3 gene [14,15], familial 
hypobetalipoproteinemia [16,17] or mutation in DGAT [18,19], have fatty liver but peripheral and 
hepatic insulin sensitivity comparable to matched subjects without mutation and NAFLD (Figure 1). 
On the other hand NAFLD is highly prevalent among patients with type 2 diabetes (up to 70%) [20] 
that show increased hepatic triglyceride accumulation independently of BMI [7]. 
Insulin resistant subjects with NAFLD show reduced insulin sensitivity not only at the level of the 
muscle but also at the level of the liver and adipose tissue [7,13,21]. In insulin-resistant conditions, the 
adipose tissue becomes resistant to the antilipolytic effect of insulin and the release of fatty acids is 
increased [22]. Insulin resistance is accompanied by increased insulin levels that, in the presence of 
increased lipolysis and/or increased fat intake, promote hepatic triglyceride synthesis [7]. Adipose 
tissue insulin resistance is quantified using the index Adipo-IR (FFA × INS) [7,23] that reflects the 
inability of insulin to suppress peripheral lipolysis. In subjects with NAFLD, even if not obese, FFA 
concentrations and Adipo-IR are increased compared to control subjects [13,24], despite an increase in 
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both hepatic and systemic lipid oxidation [13], and in VLDL-TG secretion [25,26]. Adipo-IR is also a 
marker of hepatic liver injury [21]. 
Under postprandial conditions, an important source of FFA is due to the increased spillover from 
chylomicrons [27]. The increased spillover reflects the inefficiency in dietary fat storage and results in 
excess FFA. FFA are taken up by organs saturating their oxidative capacity [13] and accumulated as 
ectopic fat, mainly as intramyocellular and hepatic lipids [28,29] but also as cardiac and pancreatic fat. 
It has been hypothesized that ectopic fat could be a defense mechanism against lipotoxicity [30,31] and 
that subjects with NAFLD develop NASH and cirrhosis only in consequence of a second hit due to 
increased inflammation and reactive oxygen species [3]. 
Figure 1. Non-alcoholic fatty liver disease (NAFLD) is not a primary determinant of 
insulin resistance, since subjects with hepatic TG accumulation due to genetic 
predisposition have a degree of hepatic and/or peripheral insulin resistance comparable to 
subjects without mutation. 
 
3. Impact of Hepatic and Visceral Fat Accumulation on Metabolic Profile 
Hepatic (IH-TG) and visceral fat (VF) are highly correlated [7,32] but independently predict the 
presence of metabolic alterations [12,33]. The direct impact of VF on glucose and lipid metabolism is 
however controversial and difficult to prove since it is a small depot compared to subcutaneous  
fat [34]. Although a correlation is found between peripheral glucose clearance and IH-TG or  
VF [7,13,35], it is unlikely that IH-TG and VF contribute directly through FFA release and lipotoxicity 
to muscle insulin resistance. Although VF accounts for as much as 38% of total fat in some extreme 
cases [34], it is unlikely that FFAs released by VF are responsible for muscular lipotoxicity [36], 
except through cytokines released by the dysfunctional tissues. 
Previous studies indicate that hepatic fat and not VF was associated with insulin resistance. When 
subjects with different IH-TG content were matched on similar VF, they showed increased hepatic and 
peripheral insulin resistance and increased VLDL-TG secretion rate but no difference was observed 
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between subjects matched for IH-TG but different VF [12] (Figure 2). Moreover, the partial VF 
reduction by omentectomy did not further improve peripheral and hepatic insulin sensitivity due to 
weight loss after surgery [37]. However, this type of analysis can be misleading, since subjects with 
normal IH-TG had high visceral fat content and subjects with matched IH-TG had on average 13% 
steatosis (Table 1). We therefore analyzed subjects with low VF and low IH-TG vs. those with both 
high VF and IH-TG, finding that insulin resistance increases proportionally to both visceral and liver 
fat (Figure 2D–F). By performing a simple correlation between hepatic and visceral fat and indexes of 
insulin resistance we observed that visceral and hepatic fat had a similar correlation [7] (Figure 3).  
Figure 2. Right panel: Insulin resistance at the level of liver, muscle and adipose tissue is 
increased proportionally to both IH-TG and VF. Data redrawn from [7]. Average data for 
IH-TG and VF are shown in Table 1. Left panel: Subjects with similar but high VF  
(~1.3 kg) had increased insulin resistance if they had high IH-TG (~25%) compared to 
subjects with low IH-TG (4%) [12]. However, when matched per IH-TG (~13%), subjects 
with low and high VF had comparable indexes of insulin resistance (reproduced with 
permission from [12]). 
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Table 1. Hepatic and visceral fat in subjects matched for VF or IHTG (data from [12]) or 
when matched for low or high IHTG (data from [7]). 
Group of subjects IHTG (%) VF Reference 
Matched on VAT 
Normal IHTG 3.6 ± 0.5 1.29 ± 0.24 kg 
[12] 
High IHTG 25.3 ± 3.5 1.34 ± 0.18 kg 
Matched on IHTG 
Low VF 13.2 ± 3.5 0.76 ± 0.08 kg 
[12] 
High VF 13.2 ± 3.3 1.94 ± 0.32 kg 
Low IH-TG 
Low VF 2.1 ± 0.6 70 ± 8 cm
2
 
[7] 
High VF 12.9 ± 1.9 84 ± 5 cm
2
 
High IH-TG 
Low VF 3.2 ± 1.6 165 ± 41 cm
2
 
[7] 
High VF 23.3 ± 1.7 159 ± 9 cm
2
 
Figure 3. Similar correlations between liver and visceral fat accumulation, hepatic insulin 
resistance (i.e., the resistance to the effect of insulin to reduce fasting hepatic glucose 
production), top panels A and B, and between liver and visceral fat and hepatic insulin 
clearance, bottom panels C and D. Data redrawn from [7]. 
 
The analysis reported in Figures 2 and 3 shows that IH-TG and VF contribute similarly to the 
increase in insulin resistance at all levels, liver, muscle and adipose tissue. In conditions of insulin 
resistance hepatic insulin sensitivity and hepatic insulin clearance are decreased proportionally to both 
hepatic and visceral fat content (Figure 3) and this is more evident in patients with Type 2 diabetes 
compared with non-diabetic subjects [7,35]. The relative contribution of IH-TG and VF to IR is in 
agreement with previous studies that have shown that obese subjects with increased VF have increased 
whole-body lipolysis compared to lean subjects [38,39] and subjects with NAFLD have preferential 
accumulation of abdominal fat. In upper body obesity, portal FFA concentrations, resulting from both 
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systemic and VF lipolysis, is significantly greater than arterial FFA concentrations, exposing the liver 
to even greater amounts of FFA [40,41].  
In the fasting state the liver is the main site of glucose production through gluconeogenesis (GNG) 
and glycogenolysis [42]. The contribution of GNG is increased in insulin resistant subjects [42] but 
because of increased circulating insulin, glycogenolysis is diminished and therefore hepatic glucose 
production remains within normal ranges, because of a mechanism named hepatic autoregulation [41,43]. 
Only when hepatic autoregulation is lost, i.e., in T2DM, both GNG and glycogenolysis are increased 
and subjects develop hyperglycemia [42]. Subjects with NAFLD, despite high circulating insulin 
levels, have reduced hepatic insulin sensitivity and postprandial glucose clearance and increased free 
fatty acid and triglyceride concentrations [7,13,21,44]. Recently, Sunny et al. have shown an increase 
in GNG in a small group of subjects with NAFLD without known T2DM compared with controls [45]. 
We have found different results in a large group of T2DM patients: GNG was increased in T2DM vs. 
controls, but not associated with liver fat content [7]. On the other hand we have observed a direct 
relationship between GNG and VF and fasting hyperglycemia, while glycogenolysis was not 
correlated to either VF or IH-TG [7,46]. Liver fat in this study ranged from 0% to 52%, while in the 
paper by Sunny et al. [45] it ranged from 0% to 21% and this could explain at least in part the different 
results. Another difference could be the relative contribution of lipolysis and FFA to GNG. It is well 
established that elevated free fatty acids (FFA) stimulate hepatic GNG [47] and VLDL-TG production 
in the face of hyperinsulinemia [40]. Despite the differences in the type of NAFLD subjects (with or 
without T2DM) and the degree of liver steatosis, the lack of correlation between GNG and hepatic TG 
shows that not all subjects with NAFLD have increased GNG and indicates that hepatic TG do not 
participate directly to increase GNG. On the other hand the two pathways are independent and with 
different turnover rates, GNG is a dynamic process [48] while hepatic TG are not changing rapidly, 
e.g., after the intake of a high-fat meal change in hepatic TG was not significant [1]. Thus, we have 
hypothesized that in conditions of insulin resistance the increased lipolysis (especially from VF) 
generates an overload of glycerol and FFA to the liver that are “cleared” through increased TG 
synthesis and GNG (where glycerol is used as a gluconeogenic substrate and FFA provide the ATP 
necessary for the GNG process through hepatic beta-oxidation). Indeed, diabetic hyperglycemia is 
proportional to increased visceral fat content and GNG [46]. 
4. Fatty Liver, Dyslipidemia and the Metabolic Syndrome 
The presence of dyslipidemia (hypercholesterolemia, hypertriglyceridemia, or both) has been 
reported in 20% to 80% of cases associated with NAFLD [49]. Liver fat content reflects the 
equilibrium between FFA flux through lipolysis, fatty acid oxidation, de-novo lipogenesis and VLDL 
secretion (Figure 4). The hepatic triglyceride accumulation is probably a consequence of saturation of 
fatty acid oxidation and VLDL secretion (Figure 4) since both these pathways are up-regulated rather 
than decreased in patients with NAFLD [13,25,26] and abnormality in apoB secretion has been 
excluded [25]. 
Postprandial hyperlipidemia and FFA spillover from chylomicrons worsen the situation [27,50]. 
Chylomicrons and triglyceride-rich lipoproteins can contribute either directly to plaque formation, 
following penetration of the arterial wall at sites of enhanced endothelial permeability, or potentially 
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indirectly following liberation of lipolytic products (such as FFA and lysolecithin) which may activate 
pro-inflammatory signalling pathways in endothelial cells [51]. 
Figure 4. Link between insulin resistance and metabolic dyslipidemia. Insulin resistance is 
associated with an increase of free fatty acids (FFAs) flux that contributes to increased TG 
production that, in turn, stimulate assembly and secretion of VLDL in hepatocytes. Fat 
accumulation in the liver is associated with oxidative stress and lipid peroxidation. 
Furthermore NAFLD subjects have increased secretion of inflammatory markers, plasma 
glucose and a decrease in HDL concentration. The consequence of this physiological 
dysfunction is increased risk for the development of diabetes and atherosclerosis and 
increased risk for coronary artery disease. 
 
In patients with NAFLD adiponectin concentrations are decreased compared to normal subjects [52,53], 
despite higher lipolysis and fatty acid concentrations associated with increased hepatic and systemic 
fatty acid oxidation. It is well established that adiponectin activates AMPK and peroxisome 
proliferator-activated receptor (PPAR)-α, thus stimulating fatty acid oxidation in liver and muscle [54]. 
Adiponectin levels also correlate inversely with plasma TGs, positively with HDL-cholesterol levels 
and LDL size, suggesting a role in lipoprotein metabolism [26,55]. Thus, low adiponectin levels in 
NAFLD can be seen as a limit in the capacity of further increase lipid oxidation in response to FFA 
overload, redirecting FFA towards re-esterification. 
Fatty Liver and Metabolic Syndrome 
It is not surprising that many studies have highlighted the association between NAFLD and several 
factors of metabolic syndrome, especially abdominal obesity, insulin resistance, increased serum 
triglycerides and small dense LDL and low HDL [7,25,26,44,56–60] (Figure 4). It has also been 
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proposed that NAFLD could be considered the hepatic manifestation of metabolic syndrome [61,62]. 
Prevalence of the metabolic syndrome in NAFLD has been estimated to vary from 18% in  
normal-weight to 67% in obese subjects [61–64]. Moreover, liver fat accumulation is very common in 
type 2 diabetes [7] and a strong link has been observed between abdominal ectopic fat accumulation 
and the development of hypertension [62,65,66]. There are plenty of data linking the liver enzymes 
ALT and GGT (both correlated with liver fat) with incidence of diabetes [67]. It has been shown that 
up to 85% of subjects with NAFLD compared to 30% in controls are insulin resistant and have 
abnormal glucose metabolism, i.e., prediabetes or T2DM, of which they were unaware [68]. This could 
explain the increased CVD risk that is often observed in patients with NAFLD highlighted by several 
epidemiological reports [9,69]. 
5. NAFLD and Cardiovascular Disease 
NAFLD is associated with increased CVD [9,60,70]. The relationship between CVD and NAFLD 
(diagnosed with either ultrasound or liver biopsy) was evaluated in studies with limited number of 
subjects [67]. Thus, larger longitudinal studies are needed to demonstrate if NAFLD is a primary cause 
of CVD and/or if NAFLD per se increases the risk of CVD mortality. Several factors that can explain 
the increased CVD risk in subjects with NAFLD as already discussed in the previous paragraphs. 
Among these there are the increased lipolysis and VLDL secretion [13,25], the atherogenic lipoprotein 
profile, i.e., increased small dense LDL fractions and reduced in HDL fractions [7,44,59,60], the 
hyperglycemia due to hepatic overproduction of glucose, the increased release of inflammatory factors 
such as fibrinogen and C reactive protein (CRP) [7,13,71]. Besides quantitative reduction in HDL 
concentration, also qualitative alterations occur [58], which may substantially contribute to the 
atherogenic risk of NAFLD. 
Fat accumulation in the liver and oxidative stress induce the secretion of inflammatory markers 
such as, IL-6, TNF-α, Fetuin-A, CRP, and fibrinogen. Fetuin-A is a protein secreted by the liver, it is a 
natural inhibitor of the insulin receptor tyrosine kinase [72] and an endogenous ligand for TLR4 
through which lipids induce insulin resistance [73]. It has been shown that Fetuin-A induces low grade 
inflammation [73,74], is associated with endothelial dysfunction [75], carotid atherosclerosis [76] and 
an increased risk of myocardial infarction (MI) and ischemic stroke (IS) [77] and type 2 diabetes [78]. 
Increased CRP promotes inflammation and accelerates atherosclerosis by increasing the expression of 
plasminogen activator inhibitor-1 and adhesion molecules in endothelial cells, inhibiting nitric oxide 
formation and increasing LDL uptake into macrophages [51]. All these metabolic abnormalities, 
common in subjects with NAFLD, have been shown to directly or indirectly promote atherosclerosis 
as confirmed by studies that showed increased carotid intima media thickness (IMT) and coronary 
atherosclerosis [9,44,60,69,71]. NAFLD is also associated with endothelial dysfunction and coronary 
artery disease [44,69,79–81]. 
The real prevalence of CV events in patients with NAFLD is still not known and probably 
underestimated. NAFLD is often not diagnosed since in the great majority of NAFLD subjects hepatic 
enzymes are within normal ranges and ultrasound technique is unable to detect NAFLD when fat 
infiltration is below 30% [82,83]. 
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5.1. Fatty Liver and Atherosclerosis 
Several studies have highlighted the association between NAFLD and increased carotid and 
coronary atherosclerosis [9,44,60]. In a large group of South Korean subjects, Sung et al. found that 
having fatty liver increases the risk of having coronary calcification and to develop type 2 diabetes [60]. 
In a Japanese cohort, age, obesity (body mass index BMI ≥ 25 kg·m−2), hypertriglyceridemia and, to a 
lesser extent, hypertension were among the variables that predicted development of fatty liver [84]. 
Previously it has been shown that hypertriglyceridemia is present in up to 64% [57] and indeed 
triglyceride and gamma glutamyl transferase (γGT) concentration, waist circumference and BMI are 
among the best predictors of fatty liver disease and related co-morbidities [44,85]. The RISC study 
showed that subjects with NAFLD are more prone to early carotid atherosclerosis even in the absence 
of metabolic syndrome and confounding diseases (hypertension, diabetes, cardiovascular diseases and 
dyslipidemia) [44]. The RISC study also documented the relationship between fatty liver and the 
presence of early plaques at carotid bifurcation, as well as the associations between carotid plaque 
presence and established atherosclerotic risk factors, family history of cardiovascular disease (FH-CVD) 
or diabetes, insulin sensitivity, serum liver enzymes, adipokines, free fatty acids and high-sensitivity 
C-reactive protein (hsCRP) [44,80].  
5.2. Fatty Liver and Endothelial Dysfunction 
Patients with NAFLD have endothelial dysfunction and a significant decrease in brachial artery 
endothelial flow-mediated vasodilatation compared to the healthy controls [20,79,86]. This decrease is 
correlated to histological features of NAFLD independent of age, sex, BMI, HOMA-insulin resistance, 
and other metabolic syndrome (MS) components [20,79]. The integrity and the maintenance of the 
endothelium wall are important in protecting against atherosclerotic vascular disease. The regeneration 
of the endothelial monolayer, when it is damaged, is performed by circulating bone marrow  
derived-endothelial progenitor cells (EPCs) and so the concentration of these in the plasma reflects the 
endothelial repair capacity [87]. Subjects with NAFLD have decreased plasma levels of EPCs that are 
correlated with arterial stiffening and endothelial dysfunction [88].  
5.3. Fatty Liver and Coronary Artery Disease (CAD) 
The presence of fatty liver is strongly associated with increased CAD risk [35,89] and CAD is a 
major cause of death in patients with NAFLD. This could also be explained by the fact that hepatic fat 
is often associated to cardiac fat and increased insulin resistance in these patients affects not only the 
liver but also other tissues like the heart [90]. The RISC study has shown that fatty liver is associated 
with an increased 10-year coronary heart disease risk score even in subjects without diabetes and 
hypertension, i.e., at low risk for CVD [44,80]. Moreover patients with NAFLD, even without 
metabolic syndrome, have more vulnerable coronary soft plaques than healthy controls [91]. In a large 
cohort of Taiwan workers, Lin et al. showed that patients with NAFLD were more likely to have CAD 
compared to patients without NAFLD, independent of obesity and other risk factors [89]. In patients 
with T2DM Targher et al. showed a higher prevalence of coronary, cerebrovascular, and peripheral 
vascular disease increased in those with NAFLD as compared to those without NAFLD [70]. 
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However, despite the strong relationship between metabolic syndrome and CAD, it has been shown 
that some parameters of metabolic syndrome, like diabetes and hypertension, were better independent 
predictors of CAD than metabolic syndrome itself and that the association between NAFLD and CAD 
was independent of other demographic and metabolic factors [92]. 
6. Conclusions 
In summary, NAFLD is associated with features of metabolic syndrome and is more prevalent 
among obese subjects and patients with type 2 diabetes independent of degree of obesity. The 
increased risk for cardio-metabolic diseases in NAFLD is caused by different factors among which 
hepatic overproduction of glucose, VLDL, inflammatory factors, C-reactive protein (CRP), and 
coagulation factors and by the presence of insulin resistance. Large trials that investigate the incidence 
of CVD and related mortality in subjects with NAFLD are needed to confirm this observation. 
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